Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06329882
Status:
RECRUITING
Last Update Posted:
2024-03-26
First Post:
2024-03-09
Brief Title:
Doxycycline in Type II Diabetes
Sponsor:
Mostafa Bahaa
Organization:
Tanta University
Study Overview
Official Title:
Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Type 2 diabetes mellitus T2DM is a chronic metabolic disease characterized by hyperglycemia weight loss and cardio-metabolic complications T2DM develops due to the progression of insulin resistance IR impairment of insulin insensitivity and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None